12/4
08:09 am
wint
Windtree Therapeutics, Inc. (NASDAQ: WINT) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
High
Report
Windtree Therapeutics, Inc. (NASDAQ: WINT) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.